- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 14
- States / cities
- Coronado, California • Los Angeles, California • San Francisco, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 901
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
- Interventions
- CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 20
- States / cities
- La Mesa, California • San Diego, California • Miami, Florida + 14 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- SAR156597, Placebo (for SAR156597)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 11
- States / cities
- Sacramento, California • Jacksonville, Florida • Chicago, Illinois + 7 more
- Conditions
- Obesity, Cardiovascular Diseases
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,946 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Covina, California • Fresno, California + 39 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BG00011, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more
- Conditions
- Healthspan Improvement, Aging, Longevity
- Interventions
- Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
- Drug · Dietary Supplement · Behavioral
- Lead sponsor
- AgelessRx
- Industry
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 20
- States / cities
- Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mucosal-Associated Lymphoid Tissue Lymphoma
- Interventions
- Vitamin D, Rituximab, Placebo
- Dietary Supplement · Biological · Other
- Lead sponsor
- Jonathan Friedberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 7
- States / cities
- Miami, Florida • Atlanta, Georgia • Iowa City, Iowa + 4 more
- Conditions
- Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Interventions
- Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- NNC0480-0389, Semaglutide, Placebo (NNC080-0389), Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 71
- States / cities
- Anniston, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
- Conditions
- Cannabis Dependence, Cannabis Withdrawal, Cognitive Deficits
- Interventions
- gabapentin 1200mg/day, Placebo, Manual-guided behavioral counseling
- Drug · Behavioral
- Lead sponsor
- The Scripps Research Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Etanercept, Adalimumab, Upadacitinib, Tocilizumab
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obese Adults
- Interventions
- VK2735 Drug, Placebo
- Drug
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Lake Forest, California • Miami, Florida
- Conditions
- Diabetes Melliuts, Type 2
- Interventions
- Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
- Other · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 17
- States / cities
- Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
- Conditions
- Chronic Plaque Type Psoriasis
- Interventions
- AIN457 300 mg, ustekinumab 45/90 mg, placebo secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 676 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
- Conditions
- Epilepsy
- Interventions
- Perampanel, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Gulf Breeze, Florida • Orlando, Florida + 8 more
- Conditions
- Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
- Interventions
- Rituximab plus immunosuppression, Placebo plus immunosuppression
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years to 70 Years
- Enrollment
- 757 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 8 more
- Conditions
- Multiple Sclerosis
- Interventions
- repository corticotropin injection, Saline
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Tobacco Use Disorder, Tobacco Use Cessation, Cannabis Use, Cannabis Use Disorder, Marijuana Use
- Interventions
- Varenicline, Counseling, Psychosocial modules
- Drug · Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 7
- States / cities
- Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more
- Conditions
- Systemic Sclerosis
- Interventions
- Placebo, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- El Cajon, California • Fullerton, California • Los Angeles, California + 12 more
- Conditions
- Hepatitis C Virus
- Interventions
- BMS-790052, Placebo, peginterferon alfa-2a, ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 35
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 9
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more
- Conditions
- Non-Alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Milk thistle (MT), Placebo, Lifestyle Modification, Fibroscan
- Drug · Behavioral · Device
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 9 Years to 22 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio